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ABSTRACT
Signaling molecules have important roles in many cellular functions, but because these 
pathways are incredibly complex, the exact mechanisms often remain unknown. One 
signaling molecule, protein kinase C alpha (PKCα), is involved in cell proliferation 
and is expressed at high levels in many cancers. Interestingly, its activity as a tumor 
promoter or tumor suppressor varies depending on the cell type for reasons not yet 
fully understood. This study aimed to investigate the role of PKCα in cell proliferation 
in order to better understand its function as a signaling molecule. To assess this, a 
knockout line was generated using CRISPR-Cas9 and human embryonic kidney 
(HEK) cells. After confirmation of knockout, proliferation studies were conducted on 
untreated knockout and wild-type cells and upon addition of 0-0.5 μg/mL of PMA and 
0-5 μg/mL of sphingosine-1-phosphate to induce proliferation. Our results indicate 
that compared with wild-type cells, untreated PKCα knockout cells exhibited reduced 
proliferation and had high percentages of cell death when treated with proliferative 
agents. This supports the hypothesis that PKCα knockout reduces proliferation in 
human embryonic kidney cells and suggests that PKCα has an important role in normal 
cell function in a tumor-promoting context.
Keywords: protein kinase C alpha (PKCα), proliferation, cancer, knockout, cell 
signaling
INTRODUCTION
Protein kinase C alpha (PKCα), a signaling molecule involved in many cellular 
processes, has an important role in cell growth and proliferation. The exact details of 
this pathway, however, are unknown, and further elucidation on the effects of PKCα 
on cell proliferation is needed. In this study, HEK cells were genetically modified using 
CRISPR-Cas9 to generate a cell line lacking PKCα. Together with a wild-type HEK 
cell line, these knockout cells were treated with varying levels of proliferative agents, 
and differences in the resulting growth rates were assessed. Developing a PKCα gene 
knockout cell line and assessing proliferation of these cells increases our understanding 
of the PKCα signaling pathway, helps to elucidate its involvement in cell growth 
and division, and contributes to hypotheses of the role it may play in the abnormal 
proliferation that is characteristic of cancer cells. In short, our findings contribute to the 
foundation for future applications of PKCα involvement in cell proliferation.
REVIEW OF LITERATURE
PKCα function
Cancer is the result of uncontrolled cell growth and is the second largest cause of 
death in the United States [5]. This abnormal cell growth is attributed to cancer-
causing mutations that typically involve malfunction of tumor-suppressor genes and 
the activation of proteins involving cell proliferation. In fact, many cancers are known 
to involve a mutation in TP53, a tumor-suppressor gene [12]. Without the proper 
function of the protein produced by that gene, p53, cell growth and division are largely 
unregulated [12]. This results in abnormal growth, often initiated by cell signaling 
molecules that have a role in normal, non-cancerous cell proliferation. One of these 
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signaling molecules, an enzyme called protein kinase C alpha (PKCα), is activated in 
normal cells by diverse signaling pathways. Various stimuli, often involving interaction 
with a membrane, can lead to PKCα involvement in differentiation, apoptosis, cellular 
transformation, motility, cell growth, proliferation, and many other cellular functions 
[13]. Importantly, PKCα has been linked to proliferation, survival, differentiation 
and motility in tumor growth but can also act as a tumor suppressor depending on 
the context [4]. In fact, past research has shown that PKCα activation leads to the 
progression of many cancers (for example, bladder and breast cancer), while it may act 
as a growth-inhibitory kinase in others (such as colon cancer and non-small cell lung 
cancer) [1], [4], [10]. Its role in cell proliferation as an application of tumor promotion 
is, however, not well understood, but targeting PKCα as a potential therapy for many 
cancers has been suggested [4]. In order to understand more about how aberrant PKCα 
signaling may be contributing to the rapid growth and division of cancer cells, a better 
understanding of the functional diversity of its proliferative role in cells is needed.
Gene knockout and human embryonic kidney cells
There are two common methods used to understand protein function: genetically 
modifying a cell line to render the gene nonfunctional, and utilizing drug inhibition to 
block protein function. In the inhibition method, proteins are still present, so although 
function is impaired, it is still possible for the drug-inhibited protein to interact with 
binding partners. Drug inhibition often also has off-target effects [16], and thus an agent 
used to inhibit PKCα function may also interfere with molecules involved in other 
proliferation pathways. For example, UCN-01 is a PKCα inhibitor with anti-tumor 
applications, but because it does not work exclusively via the PKCα pathway it cannot be 
used to understand the specific role of PKCα in proliferation and tumor promotion [4]. In 
contrast, gene knockout prevents the production of the protein altogether and eliminates 
the problems associated with inhibition. Because it exclusively targets the gene that 
codes for a protein, gene knockout yields more specific results. Knocking out the gene 
for PKCα in human embryonic kidney (HEK) cells would generate a cell line that could 
serve as a comparison to wild-type HEK cells with a normal functioning PKCα gene.
HEK cells are commonly used in cell biology and cancer research for many reasons: 
they are easy to grow and transfect, relatively inexpensive, and tumorigenic [15]. 
These properties make HEK cells a practical and meaningful tool for use in a study 
involving gene-knockout and cell proliferation. Additionally, PKCα does not act as an 
anti-proliferative factor in HEK cells, so this cell line serves as an excellent model for 
better understanding the functional role of PKCα in proliferation and tumor promotion 
[13]. A common concern involving gene-knockout involves cell viability. Removing a 
gene can have drastic effects and is often too significant of an alteration for the cells to 
survive. In 2002, researches developed a method of targeting PKC isotypes in HEK-
293 cells and demonstrated that subtype-specific differentiation was possible [6]. 
Specifically, they performed subtype-specific knockdown of PKC on HEK cells using 
short interfering RNA and grew them in normal conditions. Although this is not the same 
as gene knockout with CRISPR-Cas9, the survival of these HEK cells without active 
PKCα suggests that CRISPR-Cas9-generated PRKCA knockout HEK cells would be 
viable for use in proliferation studies.
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CRISPR-Cas9
CRISPR-Cas9 is a relatively new technology that can be used for gene knockout. Since the 
first discovery of a CRISPR locus in 1993, CRISPR-Cas9 has been researched extensively 
[7]. In 2013, researchers used it to genetically modify the genes of mice and mark them 
with a fluorescent reporter. Analysis verified that the CRISPR-Cas9 mechanism rarely 
makes errors and the use of this technology in eukaryotic cells is effective, efficient, and 
accurate [17]. Continuing this work, in 2014 CRISPR-Cas9 was successfully used for 
gene knockout in HEK-293 cells [18]. Similarly, this system could be employed to create 
a HEK cell line without PRKCA, the PKCα gene. Because of its use and reliability in 
genetic modification, CRISPR-Cas9 is important for cancer research and understanding 
the role of specific proteins, such as PKCα, in cell proliferation. Additionally, our use 
of CRISPR-Cas9 in this study makes this method accessible as a research and teaching 
tool at Olivet. The successful use of the CRISPR-Cas9 mechanism will contribute to 
the development of laboratory protocol so that this tool could be widely used by Olivet 
biology students.
Cell proliferation and proliferative agents
PKC isoforms are classified into several groups. PKCα falls into the category of classical 
PKCs (cPKCs). cPKCs are activated at a C1 domain and a C2 domain. The C1 domain 
is activated by diacylglycerol (DAG), a secondary messenger that is stimulated by 
membrane receptors, and the C2 domain allows for the binding of other molecules in 
the presence of calcium [13]. A phorbol ester, such as phorbol 12-Myristate 13-Acetate 
(PMA), is a proliferative agent known to utilize the PKCα pathway by binding at the C1 
domain [11]. Another proliferative agent, sphingosine-1-phosphate, causes proliferation 
independent of PKCα signaling [2]. The mechanism of proliferation via PKCα can 
differ depending on the cell type and activity. Activated PKCα has been documented 
to upregulate cyclin-D1, cdk4 and p21cip1, all of which can enhance proliferation 
[13]. Commonly, PKCα phosphorylates Raf-1, which leads to the activation of ERK-
MAPK (extracellular signal-regulated kinase-mitogen-activated protein kinase cascade) 
[13]. This enhances proliferation in many cell types, including HEK-293 cells [19]. 
PKCα dependent and independent proliferation in HEK cells can be evaluated through 
visual observation and the generation of a cell growth curve with doubling times. This 
can be calculated using a hemocytometer over a period of several days. In order to 
evaluate the effects of proliferative agents on cell proliferation, cells can be treated with 
various concentrations of the proliferative agent, counted, and then used to construct a 
concentration vs. cell proliferation curve.
PKCα has an important role in cell proliferation, but it is functionally diverse and 
largely not understood. Because of its involvement in tumor promotion, understanding 
this protein and its signaling pathway is important and relevant for cancer research and 
treatment. Investigating the effects of PRKCA knockout on proliferation in a cell line 
where PKCα is not tumor-suppressive can help fill this gap in research. Specifically, 
attempting to induce abnormal proliferation by mechanisms that are PKCα independent 
and dependent in a PRKCA knockout cell line will yield further understanding of its exact 
role in tumor promotion. We hypothesized that proliferation studies of wild-type and 
knockout cells under both normal conditions and when treated with PKCα-independent 
and PKCα-dependent proliferation agents would demonstrate that knocking out protein 
kinase C-alpha reduces proliferation in HEK-293 cells.
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METHODOLOGY
Generation of PRKCA knockout cells
PRKCA knockout cells were produced following the manufacture protocol provided 
by Santa Cruz Biotechnology [3]. Briefly, HEK-293 cells were seeded at a density of 
50,000 cells/well and grown in 24-well culture dishes in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum. Approximately 48 
hours later, cells reached 60-75% confluence, and culture media was replaced with 
media generated for optimal transfection of HEK-293 cells [14]. This media contained 
both the CRISPR-Cas9 KO plasmid and the homology-directed repair (HDR) plasmid 
with a fluorescent tag and also a puromycin-resistant gene insert prepared according 
to the manufacture’s protocol [3]. Briefly, three tubes were incubated then combined 
and added to each well. Tube A contained 240 μl of Optimem medium and 3.2 μg of 
the CRISPR-Cas9 KO plasmid. Tube B contained 240 μl of Optimem medium and 
3.2 μg of the HDR plasmid. Tube C contained 400 μl of Optimem medium and 16 
μl of Lipofectamine 2000. These tubes were incubated individually for 5 minutes at 
room temperature, then mixed gently and the combined solution was incubated for 20 
minutes at room temperature. Following incubation, 115 μl of the final solution was 
added to each well (twelve total) with rocking. After 24 hours, this media was replaced 
with standard DMEM and cells were grown in normal culture conditions. 
Approximately seven days post-transfection, cells were observed with fluorescent 
microscopy to confirm transfection efficiency by fluorescence. Cells were then 
grown and treated with 2.5 μg/mL of puromycin to kill cells lacking the transfected 
puromycin-resistant gene insert. This selected for cells likely to be PRKCA knockout 
cells. After growing cells for an additional seven days, they were treated with 10 μg/
mL of puromycin to select for highly-expressing homozygous knockout cells.
Western blot analysis of PKCα knockout
Puromycin resistant cells were grown and tested for PKCα presence using standard 
Western blot techniques [8]. Wild-type and knockout cells were grown in normal 
conditions in 6-well culture dishes until they reached confluence. Upon reaching 
confluence, cells were washed with PBS and treated with a lysis buffer containing 
RIPA buffer (Sigma R0278) and four protease inhibitors: PMSF (100 mM), Luepeptin 
(10 mg/mL), Aprotinin (10 mg/mL), and Pepstatin A (1 mg/mL). Lysed cells were 
collected, washed and centrifuged, and a BCA assay was performed to determine 
protein concentration in the cell lysate for wild-type and knockout cells. Lysates were 
diluted to a concentration of 1 mg/mL with SDS-PAGE loading buffer. 10% SDS-PAGE 
gel (Lonza) was loaded with 20 μl of cell lysate per lane. Three lanes were loaded for 
each cell type, and two lanes were loaded with protein molecular weight ladders. This 
procedure was run at a constant voltage of 125 V for approximately ninety minutes. 
Western blot protocol was taken from the Xcell II Blot Module User’s Manual. Transfer 
to the Western blot membrane was performed overnight in a cold room at a constant 
voltage of 12 V. Following this, the membrane was removed, treated with blocking 
buffer, and incubated in primary antibody overnight. Primary antibody was prepared 
at a dilution of 1:500. Following this, the membrane was washed and treated with the 
secondary antibody for one hour. The secondary antibody was prepared at a dilution of 
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1:12,500. Remaining western blot procedures took place in a photography dark room. 
The membrane was incubated in ECL Western Blotting Substrate (ThermoFischer) 
then exposed to film for times ranging from 10 to 45 seconds. Film was developed in 
developer solution for two to three minutes, placed in water for 30 seconds, placed in 
fixer for three minutes, and then rinsed under running water for five minutes.
Treatment with proliferative agents: sphingosine-1-phosphate and phorbol ester
PRKCA knockout and wild-type HEK-293 cells were first grown in normal conditions 
to determine viability and disruption of the normal cell cycle. Cells were grown in 
the absence of puromycin to prevent altered proliferation compared to wild-type 
cells. Cell counts were recorded for each group in duplicate over a four day period. 
Next, knockout and wild-type cells were treated with proliferative agents. The first 
of these proliferative agents, sphingosine-1-phosphate, is known to work via PKCα-
independent mechanism in HEK-293 cells [2]. Knockout and wild-type cell cultures 
were treated with concentrations of sphingosine-1-phosphate ranging from 0-5 μg/
mL, and observations of percent confluence were recorded. The second proliferative 
agent, phorbol ester, is known to activate PKCα by mimicking diacylglycerol, the 
physiological ligand for PKCα that binds along with calcium for normal PKCαactivation 
[11]. Unlike diacylglycerol, phorbol ester does not also require the binding of calcium 
to induce proliferation [11]. Knockout and wild-type cell cultures were treated with 
concentrations of phorbol ester ranging from 0-0.5 μg/mL, and observations of percent 
confluence were recorded.
Statistical analysis
A student’s t-test was used to assess significance of PKCα in cell proliferation, with a 
p-value less than or equal to 0.05 considered statistically significant.
Figure 1. Puromycin dose response curve in HEK cells two days after treatment. Cells were treated with concen-
trations of 0, 2, 2.5 and 3 μg/mL of puromycin. A concentration of 2.5 μg/mL resulted in 100% cell death.
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RESULTS
Establishing a working concentration of puromycin
In order to select for potential knockout cells using puromycin, it was important to 
establish a minimum level of puromycin that is toxic to wild-type HEK-293 cells. 
Based on previous literature, a treatment was conducted using concentrations of 0, 2, 
2.5 and 3 μg/mL puromycin. Within two days of treatment, concentrations of 2.5 and 3 
μg/mL resulted in 100% cell death. A puromycin concentration of 2.5 μg/mL was then 
selected to be used to treat transfected cells.
Confirmation of knockout
All cells were observed for RFP expression 24 hours after transfection. As expected, 
wild-type cells demonstrated a complete absence of RFP expression, and RFP was 
observed at varying levels in transfected cells. Transfected cells treated with 2.5 μg/
mL of puromycin resulted in some cell death, but surviving cells displayed normal, 
healthy growth. Control cells were treated simultaneously with 2.5 μg/mL puromycin 
and resulted in 100% cell death. The remaining transfected cells were then observed 
under fluorescent microscopy to analyze RFP expression. Figure 2 shows photographs 
depicting RFP expression in transfected cells before treatment with puromycin and one 
week post-treatment.
Figure 2. RFP expression using fluorescent microscopy in transfected cells before and after puromycin selection. 
Few transfected cells expressed RFP before puromycin selection (left), and RFP was observed at much higher levels in 
transfected cells after selection with puromycin (right).
Observations and cell counts for untreated cells
To monitor the general health of the knockout cell line, observations were made in 
comparison to wild-type HEK-293 cells. Transfected cells maintained consistent 
appearances with the wild-type cells and grew without much difficultly. They did, 
however, appear to grow at a slower rate than control cells. Cell counts were recorded 
to confirm this observation, where the cell doubling time of wild-type HEK-293 cells 
was determined to be 1.11 ± 0.04 days, while the doubling time of PRKCA KO cells 
was over twice as long at 2.27 ± 0.44 days (Figure 3, p=0.045).
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Observations of cells treated with sphingosine and PMA
As quiescent PRKCA knockout cells grew more slowly, we also sought to determine 
if inducing proliferation would result in aberrant growth in PRKCA knockout cells. 
Treatments with sphingosine (Figure 4, top) and PMA (Figure 4, bottom) were 
completed. As demonstrated in Figure 4, these observations resulted in very high levels 
of growth for control cells treated with all concentrations of PMA and sphingosine. All 
wild-type cells reached confluence within 48 hours (data not shown). Contrary to this 
observation, transfected cells treated with PMA and sphingosine did not demonstrate 
observable growth within 48 hours. By 96 hours (four days), treated transfected cells 
demonstrated high levels of death ranging from 75-100% (Figure 4, top and 4, bottom). 
These results indicate that PKCα plays a central role in proliferative induction by both 
PMA and sphingosine signaling pathways.
DISCUSSION
Determination of the role of PKCα in cell proliferation was desired, so the PRKCA 
gene knockout was attempted, growth in normal conditions assessed, and the effects 
of treating knockout cells with PKCα-dependent and independent proliferation agents 
observed.
Knockout or homozygosity?
Within two days of transfection, RFP expression was observed in transfected cells 
in varying amounts. Some of this can be attributed to the fact that transfection was 
not successful in all treated cells. In cells displaying at least some level of RFP, 
however, one possible explanation for differing levels of expression involves transient 
expression of the HDR plasmid. Transient expression occurs when the plasmid has 
not been incorporated into the genome but is actively being transcribed. To account 
for this possibility, transfected cells were grown for an additional two weeks and 
Figure 3. Cell doubling times in PRKCA knockout and wild-type HEK-293 cells. Doubling times were calculating 
from cell counts over a four day period. Wild-type: mean = 1.11 days, SE = 0.04. KO: mean = 2.27 days, SE = 0.44.
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Figure 4. PKCα knockout cells treated with sphingosine (top) and PMA (bottom) exhibit reduced viability over 
time. Top: Cells were treated with concentrations of 0, 0.1, 1 and 5 μg/mL of sphingosine-1-phosphate. Bottom: Cells 
were treated with concentrations of 0, 0.162, 0.3 and 0.5 μg/mL of PMA. Confluence was assessed four days post-treat-
ment and was observed in two cell culture wells for each cell type and treatment group. 
underwent an additional puromycin treatment. Because transient expression of the 
HDR plasmid from Santa Cruz Biotechnology lasts a maximum of seven days, any 
expression of RFP over two weeks post-transfection should be attributed exclusively to 
genomic expression of the plasmid [3]. The vast majority – approximately 90-95% – of 
remaining cells demonstrated RFP after this additional treatment, which very strongly 
suggested transfection success. 
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Western blot analysis detected PKC expression in both cell lines (data not shown). 
Bands were observed around 80 kDa, the molecular mass of PKCα and other isoforms 
of PKC, in lanes containing wild-type cell lysate as well as lanes containing knockout 
cell lysate. There were no noticeable differences in size or expression between the 
bands in any exposure times. Though this appeared to contradict other indicators of 
knockout success, there are many possible explanations for this observed result. The 
quantity of secondary antibody appropriate for use in this procedure was estimated 
based on previous literature; however, it is highly likely that the amount used was too 
high and resulted in non-specific binding. Because the secondary antibody contains 
the horseradish enzyme that indicates expression during x-ray exposure, non-specific 
binding of this antibody to other forms of PKC would yield similar band expression 
on the final x-ray film and result in a false positive. Future studies could replicate this 
procedure with varying levels of secondary antibody to yield more meaningful results. 
An additional explanation for varying levels of expression in RFP positive cells and 
the Western blot result involves the genomic location of RFP. Expression of PKCα is 
biallelic. Because of this, transfected cells may have been a combination of hemizygous 
and homozygous PRKCA knockout cells. In an attempt to select for highly-expressing 
homozygous knockout cells, we treated transfected cells with 10 αg/mL of puromycin 
(four times the concentration that is toxic to wild-type cells) before conducting 
proliferation studies. Cells that survived this treatment were determined to be probable 
knockout cells and were used for all remaining procedures; however, it is still possible 
that some of these surviving cells were hemizygous knockout, and this could explain 
the observed expression of PKCα in the Western blot analysis. 
Role of PKCα in homeostatic proliferation
Cell growth calculations yielded doubling times of 1.11 ± 0.04 days and 2.27 ± 0.44 
days for untreated wild-type cells and knockout cells, respectively. HEK cells are 
typically expected to have a doubling time of twenty-four hours, so the calculation of 
approximately a one day doubling time for wild-type cells is consistent with previous 
literature. A statistical analysis comparing the mean doubling times resulted in a p-value 
of 0.045. This suggests that the doubling time of PRKCA knockout cells is significantly 
slower than the doubling time of wild-type cells. Upon further analysis of the data, there 
are two main factors that contributed to the p-value: the small sample size and the high 
level of variance in knockout cells. Though all individual doubling times for knockout 
cells were slower than wild-type cells, they were less consistent. They appeared to 
take an especially long time to grow immediately after attachment. This observation 
is important in our understanding of how PRKCA knockout influences proliferation 
in HEK cells and how varying growth among knockout cells effects the significance 
of the data. Overall, observations and cell counts consistently demonstrated reduced 
proliferation in knockout cells, and a statistical analysis of the data yielded a significant 
result. In further studies, this data should be replicated with a larger sample, but our 
preliminary data demonstrating slowed growth supports the hypothesis that PRKCA 
gene knockout reduces proliferation in HEK cells.
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Role of PKCα during induction of proliferation
Treatments of knockout cells in high concentrations of sphingosine and PMA resulted 
in abnormal levels of cell death. This result was observed in two cell culture wells 
for each group alongside treatment of the same concentrations on wild-type cells that 
experienced rapid growth and reached confluence. To assess the significance of this data, 
it should be replicated with a larger sample size and a wider range of concentrations 
for each proliferation agent. However, we are still able to discuss several possible 
explanations for this observation within our study. Cells that have experienced gene 
knockout are often less stable; gene knockout is an intensive process, and a protein such 
as PKCα is important in many cell processes [4]. Inducing proliferation in these cells 
may be received as a stressful signal that the weakened cell cannot endure. Additionally, 
PKCα often acts as an anti-apoptotic factor, restricting the cell’s tendency to default 
toward death [13]. Cells without PKCα are, then, more likely to begin to progress 
toward apoptosis after receiving an external cellular signal. Because HEK cells are 
tumorigenic and PRKCA knockout cells became apoptotic when stimulated with high 
concentrations of proliferation agents, these data suggest that PKCα is important for 
normal cell function in a tumor-promoting context. Moreover, since untreated PRKCA 
knockout cells grew significantly slower than wild-type cells, together, these data 
further highlight the importance of PKCα as a key regulator of cellular proliferation.
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